hit counter
Achillion Pharmaceuticals, Inc. (ACHN) Stock News Sentiment & Price - Sentifly
ACHN - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Achillion Pharmaceuticals, Inc. (ACHN)

USA
Biotechnology
NASDAQ
ACHN Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACHN Latest news
GlobeNewsWire
Neutral
Achillion Shareholders Approve Agreement to be Acquired by Alexion
2019-12-19 09:24

BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.

Zacks Investment Research
Positive
5 Stocks That Pushed Russell 2000 ETF Higher
2019-11-27 12:15

Inside the best performing stocks of the Russell 2000 ETF.

24/7 Wall Street
Neutral
Are Shareholders Getting Enough in the Achillion Acquisition?
2019-10-16 09:45

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) shares skyrocketed on Wednesday morning after an announcement that the firm would be acquired by Alexion Pharmaceuticals Inc.

Seeking Alpha
Neutral
Achillion Pharmaceuticals: ACH-5228 De-Risking Gets Noticed
2019-09-30 10:52

Achillion recently reported Phase 1 results of ACH-5228 which seems to have addressed the limitations of danicopan.

GlobeNewsWire
Neutral
Achillion to Present at the Baird 2019 Global Healthcare Conference
2019-08-29 17:00

BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the Baird 2019 Global Healthcare Conference on Thursday, September 5, 2019, at 12:50 p.m. ET at the InterContinental New York Barclay in New York, NY.

Seeking Alpha
Positive
Achillion: Shifted Gears For Success
2019-08-19 12:37

Achillion Pharmaceuticals delivered extremely robust outcomes for the Phase 1 study of ACH-5228 and thereby galvanized the shares to trade multiple folds higher.

The Motley Fool
Positive
Why Achillion Pharmaceuticals Stock Jumped Today
2019-07-22 15:41

Great results from an early-stage clinical study provided a big boost to this small biotech.

Zacks Investment Research
Negative
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
2019-05-13 09:13

Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

Zacks Investment Research
Positive
Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report?
2019-04-06 09:30

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research
Positive
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
2019-03-08 11:40

Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.

Loading more news...